Immunic’s (IMUX) “Outperform” Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Immunic (NASDAQ:IMUX) in a report published on Friday morning,RTT News reports.

Several other equities research analysts also recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Immunic in a research note on Wednesday, April 30th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Thursday, May 1st. B. Riley reaffirmed a “buy” rating and set a $6.00 target price on shares of Immunic in a research note on Wednesday, April 16th. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $13.20.

Immunic Stock Performance

Immunic stock opened at $0.96 on Friday. The company’s 50 day simple moving average is $1.06 and its 200-day simple moving average is $1.08. The company has a market capitalization of $92.08 million, a price-to-earnings ratio of -0.78 and a beta of 1.73. Immunic has a 1 year low of $0.83 and a 1 year high of $2.11.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). Equities analysts expect that Immunic will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. HB Wealth Management LLC acquired a new position in Immunic during the 4th quarter worth approximately $81,000. Invesco Ltd. acquired a new position in Immunic during the 4th quarter worth approximately $37,000. Renaissance Technologies LLC grew its holdings in Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after acquiring an additional 177,542 shares in the last quarter. Barclays PLC acquired a new position in shares of Immunic in the 4th quarter valued at $84,000. Finally, 683 Capital Management LLC boosted its holdings in shares of Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after buying an additional 15,349 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.